恒瑞医药HR091506片上市许可申请获受理

Core Viewpoint - Heng Rui Medicine has received acceptance for its HR091506 tablet application from the National Medical Products Administration, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1 - The HR091506 tablet is developed using gastric retention formulation technology and features a pulsatile release characteristic [1] - The product consists of a rapid-release part and a delayed-release part, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] - The goal of HR091506 is to improve the rate of achieving target uric acid levels in patients [1]